Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia

Brain Research

Volumn 821, Issue 2, 1999, Pages 407-413

  Ross, Brian M ^a,b   Turenne, Sylvie ^a   Moszczynska, Anna ^a   Warsh, Jerry J ^a,b,c   Kish, Stephen J ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bipolar affective disorder; Glycerophosphodiesterase; Lysophospholipase; Lysophospholipid acyltransferase; Phospholipid

Indexed keywords

HALOPERIDOL; PHOSPHOLIPASE A2;

ANIMAL EXPERIMENT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME LOCALIZATION; FATTY ACID METABOLISM; FEMALE; HIPPOCAMPUS; HUMAN; MALE; MANIC DEPRESSIVE PSYCHOSIS; NONHUMAN; OCCIPITAL CORTEX; OXIDATIVE STRESS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PUTAMEN; RAT; SCHIZOPHRENIA; TEMPORAL CORTEX; THALAMUS;

1-ACYLGLYCEROPHOSPHOCHOLINE O-ACYLTRANSFERASE; ADULT; AGED; ANIMALS; BIPOLAR DISORDER; BRAIN; CALCIUM; FEMALE; HUMANS; LYSOPHOSPHOLIPASE; MALE; MIDDLE AGED; PHOSPHOLIPASES A; PHOSPHOLIPIDS; PHOSPHORIC DIESTER HYDROLASES; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA;

EID: 0033550893     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01123-3     Document Type: Article

References (39)

1. Bala-Lall S., Tekur U., Sen P. Effect of drugs influencing synthesis of prostaglandins haloperidol-induced catalepsy in rats. Indian J. Physiol. Pharmacol. 28:1984;219-222.
2. 1 macrophages. Proc. Natl. Acad. Sci. USA. 92:1995;8527-8531.
3. Brady K.T., Lydiard R.B., Malcolm R., Ballenger J.C. Cocaine-induced psychosis. J. Clin. Psych. 52:1991;509-512.
4. Breier A., Su T.P., Saunders R. Schizophrenia is associated with elevated amphetamine induced synaptic dopamine concentration: evidence from a novel positron emission method. Proc. Natl. Acad. Sci. U.S.A. 94:1997;2566-2574.
5. Deicken R.F., Fein G., Weiner M.W. Abnormal frontal lobe phosphorous metabolism in bipolar disorder. Am. J. Psychiatry. 152:1995;915-918.
6. 14C -arachidonic acid into platelet phospholipids of untreated patients with schizophreniform or schizophrenic disorders Psychiatry Res. 22:1987;275-282.
7. 31P magnetic resonance spectroscopy of the medial temporal lobe of schizophrenic patients with neuroleptic-resistant marked positive symptoms Eur. Arch. Psychiatry Clin. Neurosci. 244:1994;236-240.
8. 2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biol. Psychiatry. 22:1987;421-426.
9. Glen A.I., Glen E.M.T., Horrobin D.F., Vaddadi K.S., Spellman M., Morse-Fisher N., Ells K., Skinner F.K. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr. Res. 12:1994;53-61.
10. 2 from bovine brain cytosol. J. Neurochem. 59:1992;708-714.
11. Hoppmann R.A., Peden J.G., Over S.K. Central nervous system side effects of non-steroidal anti-inflammatory drugs. Arch. Int. Med. 151:1991;1309-1313.
12. 2 associated with schizophrenia. Schizophr. Res. 21:1996;111-116.
13. Kato T., Shiori T., Murashita J., Hamakawa H., Inubushi T., Takahashi S. Lateralized abnormality of high-energy phosphate and bilateral reduction of phosphomonoester measured by phosphorous-31 magnetic resonance spectroscopy of the frontal lobes in schizophrenia. Psychiatry Res. Neuroimaging. 61:1995;151-160.
14. Keshavan M.S., Mallinger A.G., Pettegrew J.W., Dippold C. Erythrocyte membrane phospholipids in psychotic patients. J. Psychiatry Res. 49:1993;89-95.
15. 31P MRS and MRI studies Schizophr. Res. 10:1993;241-246.
16. 2 activity in rat lung and liver. J. Nutr. 125:1995;1419-1429.
17. Lautin A., Mandio C.D., Segarnick D.J., Wod L., Mason M.F., Rotrosen J. Red cell phospholipids in schizophrenia. Life Sci. 31:1992;3051-3056.
18. Mahadik S.P., Scheffer R.E. Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins Leukotrienes Essent. Fatty Acids. 55:1996;45-54.
19. 2(s); comparison of arachidonyl-selective and -nonselective enzymes. FASEB J. 7:1993;339-348.
20. Nielsen J.A., Sparber S.B. Indomethacin potentiates the operant behavior suppressant and rectal temperature lowering effects of low doses of D-amphetamine in rats. Pharm. Biochem. Behav. 21:1984;219-224.
21. Pangerl A.M., Steudle A., Jaroni H.W., Rufer R., Gattaz W.F. Increased platelet membrane lysophosphatidylcholine in schizophrenia. Biol. Psychiatry. 30:1991;837-840.
22. 31P nuclear magnetic resonance spectroscopy: neurodevelopment and schizophrenia Schizophr. Bull. 19:1993;35-53.
23. Rahman S., Li P.P., Young L.T., Kofman O., Kish S.J., Warsh J.J. Reduced [3H]cyclic AMP binding in postmortem brain from subjects bipolar affective disorder. J. Neurochem. 68:1997;297-304.
24. 2 mechanisms in the development of stimulant sensitisation. Pharm. Exp. Ther. 276:1996;1244-1256.
25. 2. Arch. Gen. Psychiatry. 54:1997;487-494.
26. 2 activity in human brain. J. Neurochem. 63:1995;1839-1848.
27. Ross B.M., Moszczynska A., Erlich J., Kish S.J. Low activity of key phospholipid catabolic and anabolic enzymes in human substantia nigra: possible implications for Parkinson's disease. Neuroscience. 83:1998;791-798.
28. 2 activity. J. Neurochem. 70:1998;786-793.
29. 2 activity is selectively decreased in the striatum of chronic cocaine users. J. Neurochem. 67:1997;2620-2623.
30. Schwarz R.D., Uretsky N.J., Bianchine J.R. Prostaglandin inhibition of amphetamine-induced circling in mice. Psychopharmacology. 78:1982;317-321.
31. Sengupta N., Datta S.C., Sengupta D. Platelet and erythrocyte membrane lipid and phospholipid patterns in different types of mental patients. Biochem. Med. 25:1981;267-275.
32. 2 and schizophrenia. Arch. Gen. Psychiatry. 55:1998;753.
33. Stanley J.A., Williamson P.C., Drost D.J., Carr T.J., Rylett J., Malla A., Thompson T. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorous magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 52:1995;399-406.
34. Stevens J.D. The distribution of phospholipid fractions in the red cell membranes of schizophrenics. Schizophr. Bull. 6:1972;60-61.
35. Tolbert L.C., Monti J.A., O'Shields H., Walter-Ryan W., Meadows D., Smythies J.R. Defects in transmethylation and membrane lipids in schizophrenia. Psychopharmacol. Bull. 19:1993;594-599.
36. 2. J. Neurochem. 64:1995;2765-2772.
37. Weinberger D.R., Lipska B.K. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophr. Res. 16:1995;87-110.
38. 2. FEBS Lett. 377:1995;358-362.
39. Yao J.K., Yasaei P., van Kammen D.P. Increased turnover of platelet phosphatidylinositol in schizophrenia. Prostaglandins Leukotrienes Essent. Fatty Acids. 46:1992;39-46.